Efficacy of virtual reality-based cognitive behavioral group therapy in enhancing emotional well-being and quality of life in Parkinson’s disease: A randomized controlled trial
Clinical Parkinsonism & Related Disorders · 2025 · 12 · 100316
DOI: 10.1016/j.prdoa.2025.100316 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Clinical Parkinsonism & Related Disorders, 2025. Verfasst von Gooya Tayyebi und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Psychiatry, Member of the Faculty of Mazandaran University of Medical Sciences, Mazandaran, Iran. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 28 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Objective
This study evaluates the effectiveness of virtual reality-based cognitive behavioral group therapy (VR-CBGT) in improving emotional well-being and quality of life in individuals with Parkinson's disease.
Methods
A randomized controlled trial was conducted in 2023 at Roozbeh Hospital, Tehran, with 90 Parkinson's patients. Participants were randomly assigned to an intervention group receiving 12 VR-CBGT sessions over three months with a control group receiving standard medical care without psychological intervention. Emotional well-being was assessed using the Hospital Anxiety and Depression Scale (HADS), and quality of life was measured with the Parkinson's Disease Questionnaire-39 (PDQ-39) before and after the intervention. Data were analyzed using Multivariate Analysis of Covariance (MANCOVA) in SPSS-25.
Results
The intervention group demonstrated a significant improvement in emotional well-being (HADS-total score reduction of 7.2 points, P < 0.001) and quality of life (PDQ-39 total score improvement of 12.5 %, P = 0.002) compared to the control group. VR-CBGT explained 18 % of the variance in emotional well-being and 26 % in quality of life.
Conclusion
These findings highlight VR-CBGT as an effective complementary intervention for enhancing psychological health and overall quality of life in Parkinson's patients. The immersive nature of VR fosters engagement and facilitates cognitive and emotional processing, supporting its integration into multidisciplinary treatment approaches.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Psychiatry, Member of the Faculty of Mazandaran University of Medical Sciences, Mazandaran, Iran.
- Educational Psychology Department, Payame Noor University, Tehran, Iran.
- Department of Psychology, Islamic Azad University, Naein Branch, Isfahan, Iran.
- Department of Clinical Psychology, University of Social Welfare and Rehabilitation Sciences, Tehran, Iran.
- Department of Critical Care and Emergency Nursing, Zanjan Nursing and Midwifery School, Zanjan University of Medical Sciences, Zanjan, Iran.
- Department of Research, Psychology and Counseling Organization, Tehran, Iran.
Zitieren
APA
Tayyebi, G., Asadiof, F., Hashempour, B., Lotfi, M., Taheri, M., & Naeim, M. (2025). Efficacy of virtual reality-based cognitive behavioral group therapy in enhancing emotional well-being and quality of life in Parkinson’s disease: A randomized controlled trial. Clinical Parkinsonism & Related Disorders, 12, 100316. https://doi.org/10.1016/j.prdoa.2025.100316
Vancouver
Tayyebi G, Asadiof F, Hashempour B, Lotfi M, Taheri M, Naeim M. Efficacy of virtual reality-based cognitive behavioral group therapy in enhancing emotional well-being and quality of life in Parkinson’s disease: A randomized controlled trial. Clinical Parkinsonism & Related Disorders. 2025;12:100316. doi:10.1016/j.prdoa.2025.100316
BibTeX
@article{Tayyebi2025,
author = {Tayyebi, Gooya and Asadiof, Farnaz and Hashempour, Bahar and Lotfi, Mohsen and Taheri, Mostafa and Naeim, Mahdi},
title = {Efficacy of virtual reality-based cognitive behavioral group therapy in enhancing emotional well-being and quality of life in Parkinson’s disease: A randomized controlled trial},
journal = {Clinical Parkinsonism & Related Disorders},
year = {2025},
volume = {12},
pages = {100316},
doi = {10.1016/j.prdoa.2025.100316}
}
EUVIMED